Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure

Br J Haematol. 2021 May;193(4):e33-e36. doi: 10.1111/bjh.17412. Epub 2021 Mar 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / metabolism
  • Renal Insufficiency / drug therapy*
  • Renal Insufficiency / etiology
  • Renal Insufficiency / metabolism
  • Retrospective Studies
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal
  • daratumumab